You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

66 Results
Guidelines and Advice
Guidelines and Advice
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
New Drug Funding Program
    Gemcitabine and Nab-Paclitaxel - Advanced Pancreatic Cancer
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Mar 2022
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Guidelines and Advice
Sep 2017

Pages